Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00123851
Status:
COMPLETED
Last Update Posted:
2009-04-28
First Post:
2005-07-25
Brief Title:
Tarceva Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
02-269
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Beth Israel Deaconess Medical Center | OTHER |
| Sanofi-Synthelabo | INDUSTRY |
| OSI Pharmaceuticals | INDUSTRY |
| Hoffmann-La Roche | INDUSTRY |
| Genentech Inc | INDUSTRY |
| Massachusetts General Hospital | OTHER |